Patients screened (n=596)

- Did not start infliximab (n=21)

Patients started on infliximab (n=575)

- Lost to follow-up (n=71)

Evaluable patients (n=504)

Treatment discontinuations (n=158)

- Safety (n=74)
  - Non-serious AE (n=27)
  - SAE (n=47)
  - Inefficacy (n=41)
  - Elective (n=43)
  - Noncompliance with protocol (n=22)
  - Patient withdrew consent (n=17)
  - Other (n=4)

Patients still on infliximab at study end (week 74) (n=346)

---

Figure 1

(a) Diagram showing patient flow and discontinuations.

(b) Bar chart showing patients on infliximab at different weeks:
- Week 0: 575
- Week 6: 524
- Week 26: 444
- Week 50: 369
- Week 74: 346

(c) Pie chart showing treatment discontinuations:
- Discontinuation-safety (n=74) 14.7%
- Discontinuation-inefficacy (n=41) 8.1%
- Discontinuation-elective (n=43) 8.5%
- Completed to week 74 (n=346) 68.7%